AngioDynamics SVP reports PSU vesting and taxes

Chad Thomas Campbell, SVP/GM Vascular Access at AngioDynamics, reported the vesting of 6,466 shares of Common Stock on July 22, 2026, from performance share units granted July 19, 2023.

Rhea-AI Filing Summary

Chad Thomas Campbell, SVP/GM Vascular Access at AngioDynamics, reported the vesting of 6,466 shares of Common Stock on July 22, 2026, from performance share units granted July 19, 2023. A target of 22,768 performance share units could pay out 0–200%, with an additional 20% adjustment tied to relative total shareholder return over fiscal years 2024–2026; unearned units were forfeited. To cover tax withholding on the vesting, 2,330 shares were disposed at $13.82 per share.

Insider Trade Summary

22,768 shares exercised/converted

Exercise 3 txns

Insider Campbell Chad Thomas

Role SVP/GM, Vascular Access

Type	Security	Shares	Price	Value
Exercise	Performance Right F3	22,768	$0.00	$0.00
Exercise	Common Stock F1	6,466	$0.00	$0.00
Tax Withholding	Common Stock F2	2,330	$13.82	$32K

Holdings After Transaction: Performance Right — 0 contracts (Direct); Common Stock — 108,676 shares (Direct)

Footnotes (3)

1. F1. This acquisition of 6,466 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.
2. F2. The exempt disposition of 2,330 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.
3. F3. On July 19, 2023, the reporting person received a target grant of 22,768 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 6,466 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

Key Figures

Performance share unit target: 22,768 performance share units Shares issued on vesting: 6,466 shares of Common Stock Shares withheld for taxes: 2,330 shares of Common Stock +4 more

7 metrics

Performance share unit target 22,768 performance share units Target grant received on July 19, 2023

Shares issued on vesting 6,466 shares of Common Stock Issued to the reporting person based on performance

Shares withheld for taxes 2,330 shares of Common Stock Disposed to satisfy tax withholding obligations

Tax withholding price $13.82 per share Price for shares delivered to cover tax liability

Performance payout range 0% to 200% of target units Range of units earnable based on performance metrics

TSR-based adjustment 20% of total shares earned Portion adjustable by relative total shareholder return

Performance period Fiscal years 2024, 2025 and 2026 Years used to measure performance metrics for the award

Key Terms

performance share units, total shareholder return, tax withholding obligations, vesting and settlement

4 terms

performance share units financial

"represents shares acquired through the vesting and settlement of performance share units"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

total shareholder return financial

"based on total shareholder return relative to a peer group of companies"

Total shareholder return is the overall gain an investor gets from owning a stock, combining changes in the share price plus any cash payouts like dividends, and assuming those payouts are reinvested in more shares. Investors use it like a single score that shows the true return on their investment—similar to checking both the growth of a savings account and the interest earned—to compare how well different companies or investments perform over time.

tax withholding obligations financial

"made to satisfy tax withholding obligations in connection with the pre-determined vesting"

vesting and settlement financial

"represents shares acquired through the vesting and settlement of performance share units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did AngioDynamics (ANGO) report for Chad Thomas Campbell?

AngioDynamics (ANGO) reported that Chad Thomas Campbell received 6,466 shares of Common Stock from vested performance share units and had 2,330 shares withheld to satisfy tax obligations, all tied to a grant originally made on July 19, 2023.

How many performance share units were originally granted to the AngioDynamics (ANGO) executive?

On July 19, 2023, the executive received a target grant of 22,768 performance share units. Between 0% and 200% of this target could be earned based on performance metrics for fiscal years 2024, 2025 and 2026, plus a total shareholder return adjustment.

How many AngioDynamics (ANGO) shares ultimately vested from the performance grant?

Based on performance over the measurement period, 6,466 shares of Common Stock were issued to the reporting person under the performance share unit grant. According to the disclosure, the remaining units were forfeited and no longer outstanding.

What tax-related share disposition was reported in the AngioDynamics (ANGO) Form 4?

The Form 4 shows an exempt disposition of 2,330 shares of Common Stock at $13.82 per share. These shares were withheld to satisfy tax withholding obligations arising from the pre-determined vesting of the performance share unit award.

What performance conditions applied to the AngioDynamics (ANGO) performance share units?

The performance share units could pay between 0% and 200% of the 22,768-unit target based on pre-determined metrics for fiscal years 2024–2026. Additionally, up to 20% of total shares earned could be adjusted by relative total shareholder return versus a peer group.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 06:11 PM Accepted by SEC EDGAR 07/24/2026 - 06:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Campbell Chad Thomas

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP/GM, Vascular Access

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2026		M		6,466(1)	A	$0	111,006	D
Common Stock	07/22/2026		F		2,330(2)	D	$13.82	108,676	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Right	(3)	07/22/2026		M			22,768	(3)	(3)	Common Stock	22,768	$0	0	D

Explanation of Responses:

1. This acquisition of 6,466 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.

2. The exempt disposition of 2,330 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.

3. On July 19, 2023, the reporting person received a target grant of 22,768 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 6,466 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

	/s/ Lawrence T. Weiss, Attorney in Fact	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)